May 14, 2012

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

Share this content:
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
 
Sponsors and Collaborators
Argos Therapeutics
 
Contact
Jill Yarbrough
919-287-6309
 
Investigators
Robert Figlin, MD, FACP
Cedars-Sinai Medical Center
 
Christopher G Wood, MD, FACP
M.D. Anderson Cancer Center
 
ClinicalTrials.gov Identifier
 
 
Recommended for you

Related Resources

News
You must be a registered member of Cancer Therapy Advisor to post a comment.
Click here to login   |  Click here to register

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs